1-(2-hydroxyaryl)-alkane-1-on-oximes-procedure of preparation and use in pharmaceuticals

A pharmaceutical composition useful for inhibiting lipoxygenase comprising, as an active component, a compound of the formula ##STR4## wherein R is C.sub.1 -C.sub.18 alkyl or aralkyl;

• R.sup.1 and R.sup.3 are ech hydrogen, C.sub.1 -C.sub.12 alkyl, or chlorine;
• R.sup.2 is hydrogen, C.sub.1 -C.sub.12 alkyl or OR.sup.4, and R.sup.4 is C.sub.1 -C.sub.18 alkyl, C.sub.3 -C.sub.8 cycloalkyl or aralkyl;
• and
• Z is hydrogen, C.sub.1 -C.sub.12 alkyl, COR.sup.5, or CONHR.sup.5, and R.sup.5 is an aromatic or aliphatic residue, with the proviso that when
• Z, R.sup.2 and R.sup.3 are each hydrogen, R is C.sub.7 -C.sub.18 alkyl,
• in an amount effective to inhibit lipoxygenase, in combination with a pharmaceutically acceptable carrier, wherein the composition is in unit dosage form.

A pharmaceutical composition useful for inhibiting lipoxygenase comprising, as an active component, a compound of the formula ##STR5## wherein Z is hydrogen, C.sub.1 -C.sub.12 alkyl, COR.sup.5, or CONH.sup.5, and R.sup.5 is an aromatic or aliphatic residue;

• where Z is hydrogen,
• R is C.sub.7 -C.sub.18 alkyl or aralkyl;
• R.sup.1 is hydrogen, C.sub.1 -C.sub.12 alkyl, or chlorine;
• R.sup.2 and R.sup.3 are each hydrogen, with the proviso that when Z, R.sup.2 and R.sup.3 are each hydrogen, R is C.sub.7 -C.sub.18 alkyl, and when Z is C.sub.1 -C.sub.12 alkyl, COR.sup.5, or CONHR.sup.5, and R.sup.5 is an aromatic or aliphatic residue,
• R is C.sub.1 -C.sub.18 alkyl or aralkyl;
• R.sup.1 is hydrogen, C.sub.1 -C.sub.12 alkyl, or chlorine;
• R.sup.2 is C.sub.1 -C.sub.12 alkyl or OR.sup.4, and R.sup.4 is C.sub.1 -C.sub.18 alkyl, C.sub.3 -C.sub.8 cycloalkyl or aralkyl;
• and
• R.sup.3 is C.sub.1 -C.sub.12 alkyl or chlorine
• in an amount effective to inhibit lipoxygenase, in combination with a pharmaceutically acceptable carrier, wherein the composition is in aerosol form.

A pharmaceutical composition useful for inhibiting lipoxygenase comprising, as an active component, a compound selected from the group consisting of

• 3-chloro-2-hydroxy-caprophenone-oxime,
• 5-chloro-2-hydroxy-caprophenone-oxime,
• 4-methyl-2-hydroxy-caprophenone-oxime,
• 5-methyl-2-hydroxy-caprophenone-oxime,
• 5-methyl-2-hydroxy-caprophenone-(N-phenylcarbamoyl)-oxime,
• 3-chloro-2-hydroxy-laurophenone-oxime,
• 5-chloro-2-hydroxy-laurophenone-oxime,
• 5-methyl-2-hydroxy-laurophenone-oxime,
• 4-n-butoxy-2-hydroxy-acetophenone-oxime,
• 4-n-pentoxy-2-hydroxy-acetophenone-oxime,
• 4-n-decyloxy-2-hydroxy-acetophenone-oxime,
• 4-n-hexadecyloxy-2-hydroxy-acetophenone-oxime,
• 4-n-octadecyloxy-2-hydroxy-acetophenone-oxime,
• 4-benzyloxy-2-hydroxy-acetophenone-oxime,
• 4-n-decyloxy-2-hydroxy-propiophenone-oxime,
• 4-n-dodecyl-2-hydroxy-propiophenone-oxime,
• 4-cyclohexyl-2-hydroxy-propiophenone-oxime,
• 4-n-pentoxy-2-hydroxy-caprophenone-oxime,
• 4-n-decyloxy-2-hydroxy-caprophenone-oxime,
• 4-n-octyloxy-2-hydroxy-laurophenone-oxime, and
• 4-n-decyloxy-2-hydroxy-laurophenone-oxime,
• in an amount effective to inhibit lipoxygenase, in combination with a pharmaceutically acceptable carrier, wherein the composition is in aerosol form.

A pharmaceutical composition useful for inhibiting lipoxygenase comprising, as an active component, a compound of the formula ##STR6## wherein Z is C.sub.1 -C.sub.12 alkyl, COR.sup.5, or CONHR.sup.5, and R.sup.5 is an aromatic or aliphatic residue;

• R is C.sub.1 -C.sub.18 alkyl or aralkyl;
• R.sup.1 is hydrogen, C.sub.1 -C.sub.12 alkyl, or chlorine;
• R.sup.2 is C.sub.1 -C.sub.12 alkyl or OR.sup.4, and R.sup.4 is C.sub.1 -C.sub.18 alkyl, C.sub.3 -C.sub.8 cycloalkyl or aralkyl;
• and
• R.sup.3 is C.sub.1 -C.sub.12 alkyl, or aralkyl
• in an amount effective to inhibit lipoxygenase, in combination with a pharmaceutically acceptable carrier.